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Abstract: The interferon-free combination of once-daily faldaprevir 120 mg, twice-daily 
deleobuvir 600 mg, and weight-based ribavirin was evaluated in two Phase III studies 
(HCVerso1, HCVerso2) in hepatitis C virus genotype-1b-infected, treatment-naïve patients, 
including those ineligible for peginterferon (HCVerso2). Patients without cirrhosis were 
randomized to 16 weeks (Arm 1; n=208 HCVerso1, n=213 HCVerso2) or 24 weeks (Arm 2; 
n=211 in both studies) of faldaprevir + deleobuvir + ribavirin. Patients with compensated 
cirrhosis received open-label faldaprevir + deleobuvir + ribavirin for 24 weeks (Arm 3; 
n=51, n=72). Primary endpoints were comparisons of adjusted sustained virologic response 
(SVR) rates with historical rates: 71% (HCVerso1) and 68% (HCVerso2). Adjusted SVR12 
rates were significantly greater than historical controls for Arms 1 and 2 in HCVerso2 (76%, 
95% confidence interval [CI] 71–81, P=0.002; 81%, 95% CI 76–86, P<0.0001) and Arm 2 
in HCVerso1 (81%, 95% CI 77–86, P<0.0001), but not for Arm 1 of HCVerso1 (72%, 95% 
CI 66–77, P=0.3989). Unadjusted SVR12 rates in Arms 1, 2, and 3 were 71.6%, 82.5%, and 
72.5%, respectively, in HCVerso1 and 75.6%, 82.0%, and 73.6%, respectively, in HCVerso2. 
Virologic breakthrough and relapse occurred in 24-week arms in 8%–9% and 1% of patients, 
respectively, and in 16-week arms in 7%–8% and 9%–11% of patients, respectively. The 
most common adverse events were nausea (46%–61%) and vomiting (29%–35%). Adverse 
events resulted in discontinuation of all medications in 6%–8% of patients. In treatment-
naïve patients with hepatitis C virus genotype-1b infection, with or without cirrhosis, 
faldaprevir + deleobuvir + ribavirin treatment for 24 weeks resulted in adjusted SVR12 rates 
significantly higher than historical controls. Both studies were registered in ClinicalTrials.
gov (NCT01732796, NCT01728324).
Keywords: chronic hepatitis C, NS3 protease inhibitor, nonnucleoside polymerase inhibitor, 
cirrhosis, antiviral
Introduction
Chronic infection with hepatitis C virus (HCV) is a major cause of morbidity and 
mortality worldwide.1–3 Among the numerous genotypes of HCV, genotype-1 (GT-1) 
is the most prevalent in North America and Europe and has been difficult to treat with 
peginterferon-α (PegIFN) and ribavirin.2,4,5 There are two major subtypes of HCV 
GT-1, 1a and 1b, with 1b being the most prevalent subtype outside of North America.5 
Although rates of sustained virologic response (SVR) improved markedly with the 
advent of the first HCV NS3/4A serine protease inhibitors telaprevir and boceprevir, 
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 trials, the development of faldaprevir and deleobuvir has 
been terminated. Nevertheless, these studies, which include a 
large number of patients with compensated cirrhosis, provide 
valuable information about treating chronic hepatitis C with 
the combination of an NS3 inhibitor and a nonnucleoside 
NS5B inhibitor that may be relevant to the use of other DAA 
regimens.
Methods
Study design and patients
HCVerso1 and HCVerso2 were multicentered, randomized, 
placebo-controlled, partially double-blind Phase III studies. 
HCVerso1 was carried out at multiple sites in North America 
and Europe between December 2012 and April 2014, and 
HCVerso2 was carried out at multiple sites in North America, 
Australia, New Zealand, and Europe between November 
2012 and March 2014. In both studies, eligible patients were 
aged 18–75 years with a diagnosis of chronic HCV GT-1b 
infection, as determined by positive antiHCV antibodies 
and HCV RNA ≥1,000 IU/mL at screening, in addition to at 
least one of the following: a liver biopsy signifying chronic 
HCV infection; a positive antiHCV antibody or HCV RNA 
test; or elevated alanine aminotransferase (ALT) levels at 
least 6 months prior to the screening visit. Patients with 
compensated liver cirrhosis were also included. Compensated 
liver cirrhosis was defined as Ishak Grade ≥5 or METAVIR 
≥4 on a liver biopsy within 3 years, or liver stiffness of 
≥13 kPa on a FibroScan within 6 months of randomization. 
All enrolled patients were naïve to IFN, PegIFN, ribavirin 
treatment, or any DAA agent for HCV infection. Exclusion 
criteria included mixed-genotype HCV, HCV GT-1a or GT-1 
subtype undefined, nonHCV-related liver disease, hepatitis B 
virus infection, human immunodeficiency virus infection, and 
decompensated liver disease. In HCVerso1, historical studies 
used for comparison included only those patients who were 
eligible for PegIFN/ribavirin. Therefore, patients who would 
likely be considered ineligible for PegIFN and/or ribavirin 
were excluded. In HCVerso2, an extended population was 
included based on modified exclusion criteria allowing 
inclusion of patients who would have been ineligible for 
PegIFN; for example, patients with preexisting psychiatric 
conditions, uncontrolled abnormal thyroid function, active 
autoimmune-mediated disease known to be exacerbated by 
PegIFN, or diabetes mellitus (Table S1). PegIFN ineligibility 
was based on the investigators’ clinical judgment.
Study protocols were approved by the appropriate institu-
tional review board. The study was undertaken in accordance 
these agents presented new challenges by adding to the 
already existing substantial toxicity of PegIFN-based treat-
ment regimens.2,6–8 More recently, several new antiviral agents 
have provided options with simplified and shorter treatment 
duration for patients with HCV GT-1;9–13 however, at the 
time of the HCVerso studies, treatment options mainly still 
required the inclusion of PegIFN/ribavirin in the regimen.9,10 
Patients infected with HCV frequently display contraindica-
tions to PegIFN treatment (eg, neuropsychiatric disorders, 
low white blood cell count or platelet count, autoimmune 
disease). Recognizing the substantial limitations of interferon 
(IFN)-based regimens, attention is increasingly focused 
toward combining direct-acting antiviral (DAA) agents in 
IFN-free treatment strategies.14
Faldaprevir is an HCV NS3/4A protease inhibitor with 
potent and similar in vitro activity against HCV GT-1a and 
-1b and a pharmacokinetic profile that supports once-daily 
dosing.15,16 Deleobuvir (BI 207127) is a nonnucleoside 
inhibitor of HCV NS5B RNA polymerase that binds revers-
ibly to thumb-pocket I of NS5B, thereby achieving potent 
and specific antiviral activity.17,18 In vitro and in a Phase I 
study, deleobuvir was more active against GT-1b than against 
GT-1a.17,18 The IFN-free combination of once-daily faldapre-
vir plus either twice-daily or three-times daily deleobuvir, 
with or without ribavirin, has been investigated in Phase II 
clinical studies in treatment-naïve patients with chronic HCV 
GT-1 infection.19–21 In the SOUND-C2 study, 28 weeks of 
treatment with faldaprevir plus twice-daily deleobuvir and 
ribavirin was the most effective, driven by a favorable toler-
ability profile and an SVR 12-week posttreatment (SVR12) 
of 85% in patients with GT-1b infection.20 SVR12 rates 
were lower without ribavirin, indicating that ribavirin is an 
important component of the regimen. Response rates were 
also lower among patients with HCV GT-1a, particularly 
those with IL28B nonCC genotypes who experienced a high 
rate of on-treatment breakthrough. The SOUND-C3 study 
demonstrated that reduction of the treatment duration of 
faldaprevir plus twice-daily deleobuvir and ribavirin to 16 
weeks was effective in treatment-naïve patients with HCV 
GT-1b infection, resulting in an SVR12 in 19/20 (95%);21 
therefore, Phase III studies assessed 16- and 24-week treat-
ment durations in GT-1b-infected patients only.
Here, we present the results of two Phase III studies 
(HCVerso1, NCT01732796; HCVerso2, NCT01728324) that 
aimed to confirm the efficacy and safety of 16 or 24 weeks 
of treatment with faldaprevir in combination with deleobuvir 
and ribavirin in treatment-naïve patients with chronic HCV 
GT-1b infection. Based on the results of these Phase III 
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with the Declaration of Helsinki and the International Confer-
ence on Harmonization guidelines. Written informed consent 
was provided by all patients before participation in the study.
Randomization and treatments
In both studies, patients without cirrhosis were randomly 
assigned in a 1:1 ratio, using an interactive response tool, to 
treatment Arms 1 or 2. Patients with compensated cirrhosis 
were directly assigned to Arm 3. Randomization was stratified 
by PegIFN eligibility in HCVerso2. Patients without cirrho-
sis in Arms 1 and 2 received oral treatment with faldaprevir 
120 mg once daily, deleobuvir 600 mg twice daily, and stan-
dard weight-based doses of ribavirin for 16 and 24 weeks, 
respectively (Figure S1). Blinding of investigators and patients 
to treatment duration was achieved through the administration 
of placebo: in HCVerso1, patients in Arm 1 received 16 weeks 
of active treatment followed by 8 weeks of placebo treatment; 
in HCVerso2, patients in Arm 1 received an 8-week lead-in 
with placebo prior to receiving 16 weeks of active treatment. 
Patients and investigators were unblinded following database 
lock after the last patient completed assessment of SVR12. 
In Arm 3, patients with compensated cirrhosis received 
open-label faldaprevir, deleobuvir, and ribavirin (dosed as in 
Arms 1 and 2) for 24 weeks. All patients were given a single 
loading dose of faldaprevir 240 mg on Day 1, followed by 
120 mg per day from Day 2 onward. Study treatments were 
administered with food (a requirement of ribavirin). Dose 
reductions or temporary discontinuation (with reintroduction 
at the lowest dose as soon as possible) was permitted only for 
ribavirin. Concomitant use of immunomodulators, systemic 
antiviral agents (except for the treatment of herpes simplex 
infection or influenza A), silibinin (or other extracts from the 
milk thistle), or medications that could cause photosensitiv-
ity reactions was not permitted. Patients were advised to 
protect any uncovered skin area (including hands, face, and 
lips) from sun or ultraviolet (UV) light exposure with a daily 
sunblock cream and a lip balm with sun protection factor ≥50 
providing both UVA and UVB protection during the treatment 
period. Patients were to be followed for up to 96 weeks after 
the end of treatment (EOT); however, after the termination 
of deleobuvir development, the extended follow-up period 
was shortened to 24 weeks after the EOT for responders 
(with SVR12) and to 48 weeks after the EOT for non-
responders, provided they had not started an alternative HCV 
treatment.
All study treatments were discontinued in the event of a 
lack of virologic response, defined as virologic breakthrough 
(an increase in HCV RNA of ≥1 log
10
 from quantifiable nadir 
or HCV RNA ≥25 IU/mL following an earlier decrease to 
<25 IU/mL, confirmed by a second consecutive measurement 
of ≥25 IU/mL within a 2-week duration) or failure to achieve 
HCV RNA <25 IU/mL and HCV RNA ≥25 IU/mL at any 
time after Week 8. Patients with a lack of virologic response 
could switch to treatment with faldaprevir (12 or 24 weeks) in 
combination with PegIFN and ribavirin (24 or 48 weeks), with 
treatment duration determined by response-guided therapy.
Endpoints
The primary objective of the studies was to compare adjusted 
SVR12 rates for 16- and 24-week regimens, including 
patients with cirrhosis, with historical SVR rates of 71% 
for PegIFN-eligible patients and 50% for PegIFN-ineligible 
patients. The secondary objective was to evaluate whether 
there is a clinically meaningful difference in efficacy between 
16- and 24-week treatment durations. Plasma HCV RNA lev-
els were measured using the quantitative COBAS® TaqMan® 
HCV/HPS assay (version 2; Roche Molecular Diagnostics, 
Pleasanton, CA, USA), with a limit of detection between 10 
and 20 IU/mL and a linear range of 25–3.91×108 IU/mL. 
HCV RNA levels are reported as <25 IU/mL (detected 
or undetected), <25 IU/mL (undetected), or <25 IU/mL 
(detected).
The primary endpoint in both studies was SVR12, which 
was defined as HCV RNA <25 IU/mL (detected or unde-
tected) at 12 weeks after the end of active treatment. Key 
secondary endpoints were SVR at 4 and 24 weeks after com-
pletion of active treatment (SVR4 and SVR24,  respectively). 
Further efficacy endpoints included: HCV RNA<25 IU/mL 
undetected at Week 4; HCV RNA <25 IU/mL detected or 
undetected at Week 4; HCV RNA <25 IU/mL undetected at 
Week 12; EOT response (HCV RNA <25 IU/mL undetected 
at the end of planned treatment); and virologic breakthrough 
and relapse posttreatment (HCV RNA >25 IU/mL in patients 
who achieved EOT response).
Safety assessment included the incidence of adverse 
events (AEs) and changes in laboratory parameters during 
the course of treatment, which were graded as mild (Grade 1), 
moderate (Grade 2), severe (Grade 3), or potentially life-
threatening (Grade 4) using the Division of AIDS Table for 
Grading the Severity of Adult and Pediatric Adverse Events.22 
Photosensitivity was graded as mild, moderate, or severe 
according to a dermatologic management plan.
Resistance testing
Virology plasma samples from all visits at which HCV RNA 
was also measured were collected and stored for  monitoring 
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of drug resistance. Population-based sequence analysis 
of the HCV NS3/4A protease (codons 1–685) and NS5B 
 polymerase (codons 1–592) was performed for baseline 
plasma samples from all patients and for postbaseline sam-
ples, including posttreatment follow-up from patients who did 
not achieve SVR if HCV RNA rebound was ≥1,000 IU/mL 
(limit for HCV gene amplification). Treatment-emergent 
amino acid changes were identified relative to patients’ 
respective baseline sequence.
Statistical analysis
The primary efficacy and safety analyses were undertaken 
for all randomized patients who received at least one dose of 
study medication (intention-to-treat population).
Historical control rates were based on SVR data for GT-1b 
patients included in Phase III trials of telaprevir and bocepre-
vir: the lowest SVR rate seen in these studies was 71% with 
boceprevir plus PegIFN/ribavirin response-guided therapy in 
treatment-naïve patients.23–25 As the historical trials included 
patients with cirrhosis, whereas the HCVerso trials separated 
patients with cirrhosis into a nonrandomized treatment arm, 
for the purposes of the comparison, SVR12 rates in both 
studies were adjusted using a weighted average (89% times 
the response rate in noncirrhotic + 11% times the response 
rate in cirrhotic), where 11% is the highest rate of inclusion 
of patients with cirrhosis in earlier trials of DAAs + PegIFN/
ribavirin.23 For this adjustment, the SVR12 rate from Arm 3 
(24 weeks in patients with cirrhosis) was used for both the 
16- and 24-week treatment arms. For HCVerso2, the historical 
response rate was adjusted to take into account the inclusion of 
PegIFN-ineligible patients. For these patients, a response rate 
of 50% was used based on several assumptions (see Supple-
mentary materials,  including Table S2, for details). The overall 
historical control rate was calculated as 68%: 86% times the 
control response rate in PegIFN-eligible patients (71%) + 14% 
times the control response rate in PegIFN-ineligible patients 
(50%), where 14% is the proportion of PegIFN-ineligible 
patients in the study. Statistical comparisons were made using 
a one-sided z-test with alpha = 0.025. For the comparison of 
16- and 24-week treatment in patients without cirrhosis (sec-
ondary objective), in HCVerso 2, the Greenland formula with 
continuity correction was applied in pairwise comparisons 
of the SVR12 rate (including 95% confidence interval [CI]), 
with adjustment for stratification. In HCVerso1, a two-sided 
independent t-test with continuity correction was used. The 
influence of baseline factors on SVR12 rate was assessed in 
a subgroup analysis. Logistic regression analysis was also 
carried out for both studies to explore the potential influence 
of baseline factors or covariates on response.
For HCVerso1, a sample size of 390 noncirrhotic patients 
was determined to provide 90% power in order to detect a 
significant difference in SVR12 compared with historical 
controls (one-sample z-test with a one-sided alpha of 0.025), 
assuming an SVR12 rate of 81%, and to provide 80% power 
in order to detect a significant difference between 16- and 
24-week treatment durations, assuming an SVR12 rate of 
approximately 82.5% in Arm 2 and a clinically relevant 
difference of 12%. For HCVerso2, a sample size of 420 
noncirrhotic patients was determined to provide 83% power 
in order to detect a significant difference in SVR12 compared 
with historical controls (one-sample z-test with a one-sided 
alpha of 0.025), assuming an SVR12 rate of 80% for PegIFN-
eligible patients and 60% for PegIFN-ineligible patients, 
and to provide 80% power in order to detect a significant 
difference between 16- and 24-week treatment durations, 
assuming an SVR12 rate of approximately 80% in Arm 2 
and a clinically relevant difference of 12%. Sample size for 
cirrhotic patients was defined as between 50 and 70 patients, 
based on potential enrollment rate.
Results
Patients
In HCVerso1, 470 patients were randomized into Arms 1 
and 2 (noncirrhotic) or allocated to Arm 3 (compensated 
cirrhosis) and received at least one dose of study medica-
tion (Figure 1A). In HCVerso2, 496 patients were random-
ized into Arms 1 and 2 (noncirrhotic) or allocated to Arm 
3 (compensated cirrhosis) and received at least one dose of 
study medication (Figure 1B). Discontinuation of faldaprevir, 
deleobuvir, or ribavirin during the active treatment period 
occurred in 81 (17%), 82 (17%), and 84 (18%) patients, 
respectively, in HCVerso1, and in 86 (17%), 86 (17%), and 
89 (18%) patients, respectively, in HCVerso2. The most 
frequent reasons for discontinuation of active treatment 
were AEs and lack of efficacy (Figure 1). In Arm 1, treat-
ment discontinuation during the placebo treatment period 
occurred in 20 (9.6%) patients in HCVerso1 (placebo given 
after active treatment), mostly for lack of efficacy, and in 
two (1%) patients in HCVerso2 (placebo given prior to 
active treatment), one for an AE and the other one follow-
ing a protocol violation (Figure 1). Baseline demographics 
and disease characteristics were generally balanced across 
the randomized treatment groups in both studies (Table 1). 
In both studies, among patients with cirrhosis (Arm 3), the 
percentage of males and the mean age were higher than in 
Arms 1 and 2. In HCVerso2, most patients were eligible to 
receive PegIFN; overall, 13% (65/496) were judged to be 
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PegIFN ineligible. The most common reasons for PegIFN 
ineligibility were psychiatric disease (51% [33/65]) and 
autoimmune conditions (25% [16/65]).
Virologic response
Results for the primary endpoint of SVR12 are shown in Figure 
2. Compared with the historical control, the adjusted SVR12 
rates after treatment with faldaprevir + deleobuvir + ribavirin 
were superior for the 24-week arm of HCVerso1 and for both 
the 16- and 24-week arms of HCVerso2 ( Figure 2A and C). In 
HCVerso1, 24 weeks of treatment resulted in a higher SVR12 
rate than 16 weeks of treatment among patients without cirrhosis 
(Figure 2B). In HCVerso2, there was no significant difference 
in SVR12 rates between the 16- and 24-week treatment arms 
(Figure 2D). Among patients with compensated cirrhosis, the 
SVR12 rate was 72.5% in HCVerso1 and 73.6% in HCVerso2. 
Further virologic endpoints are summarized in Table 2. In 
both studies, the Week 4 responses were similar in the 16- and 
24-week non-cirrhotic treatment groups. In the 16-week groups, 
SVR12 was higher among patients with HCV RNA undetected 
Figure 1 Patient disposition in HCVerso1 (A) and HCVerso2 (B)
Notes: aAdverse event 11, lack of efficacy 7, lost to follow-up 2, withdrawal 4, other 2. bAdverse event 12, lack of efficacy 8, lost to follow-up 2, withdrawal 4, other 1. 
cAdverse event 12, lack of efficacy 7, lost to follow-up 2, withdrawal 4, other 2. dAdverse event 5, lack of efficacy 13, withdrawal 1, other 1. eAdverse event 4, lack of efficacy 
13, withdrawal 2. fAdverse event 4, lack of efficacy 13, withdrawal 1, other 1. gAdverse event 16, lack of efficacy 17, withdrawal 8, other 1. hAdverse event 16, lack of efficacy 
18, withdrawal 8. iAdverse event 17, lack of efficacy 17, withdrawal 8, other 1. jAdverse event 4, lack of efficacy 4, withdrawal 2, other 3. kAdverse event 4, lack of efficacy 
5, withdrawal 2, other 2. lAdverse event 5, lack of efficacy 4, withdrawal 2, other 3. mAdverse event 13, lack of efficacy 12, withdrawal 6, other 3. nAdverse event 16, lack of 
efficacy 11, withdrawal 5, other 3. oAdverse event 1, protocol violation 1. pAdverse event 14, lack of efficacy 14, withdrawal 9, other 1. qAdverse event 15, lack of efficacy 14, 
withdrawal 9, other 1. rAdverse event 4, lack of efficacy 8, withdrawal 2. sAdverse event 5, lack of efficacy 7, withdrawal 2, other 1.
Abbreviations: C, compensated cirrhosis; DBV, deleobuvir; DC, discontinuation; FDV, faldaprevir; NC, no cirrhosis; RBV, ribavirin.
Enrolled
n=691
Randomized and treated
n=470
Arm 1: FDV + DBV + RBV
16 weeks, NC
n=208
Arm 2: FDV + DBV + RBV
24 weeks, NC
n=211
Arm 3: FDV + DBV + RBV
24 weeks, C
n=51
Completed all
study treatments
n=162
Completed all
study treatments
n=168
Completed all
study treatments
n=37
Discontinued treatment, n=46
in active treatment period:
In placebo period:
FDV n=26a
DBV n=27b
RBV n=27c
FDV n=20d
DBV n=19e
RBV n=19f
.
.
.
.
.
.
Discontinued treatment, n=43
in active treatment period:
FDV n=42g
DBV n=42h
RBV n=43i
.
.
.
Discontinued treatment, n=14
in active treatment period:
FDV n=13j
DBV n=13k
RBV n=14l
.
.
.
Enrolled
n=755
Randomized and treated
n=496
Arm 1: FDV + DBV + RBV
16 weeks, NC
n=213
Arm 2: FDV + DBV + RBV
24 weeks, NC
n=211
Arm 3: FDV + DBV + RBV
24 weeks, C
n=72
Completed all
study treatments
n=172
Completed all
study treatments
n=173
Completed all
study treatments
n=57
Discontinued treatment, n=37
in active treatment period:
In placebo period:
FDV n=34m
DBV n=34m
RBV n=35n
...
.
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.
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.
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at Week 4 than among those with HCV RNA <25 IU/mL 
detected at Week 4. Reasons for not achieving SVR12 are sum-
marized in Table 3. The frequency of on-treatment virologic 
failure (mostly occurring before 16 weeks) was similar in the 
16- and 24-week noncirrhotic treatment groups (7%–9%) and 
slightly higher among patients with cirrhosis (13%–14%). Pre-
mature discontinuation for reasons other than lack of efficacy 
(mostly for AEs or “withdrawal”) (Figure 1) accounted for a 
lack of SVR12 in between 5% and 10% of patients across treat-
ment groups. Relapse (among patients who completed planned 
treatment and had undetectable HCV RNA at the EOT) was the 
most common reason for lack of SVR12 among patients in the 
16-week treatment groups. The rate of relapse was numerically 
lower in the 24-week (noncirrhotic) treatment groups than in 
the 16-week treatment groups.
In HCVerso1, among patients without cirrhosis, the 
rates of SVR12 were higher for 24 weeks than 16 weeks 
of treatment across several baseline subgroups, including 
patients with nonCC IL28B genotype, patients with baseline 
viral load ≥800,000 IU/mL, and patients 40–65 years of age 
(Figure 3). Differences were less pronounced in HCVerso2, 
where only patients with baseline viral load ≥800,000 IU/mL 
showed a clear difference in SVR12 rates between 16- and 
24-week treatment arms. Multivariate analysis identified the 
 associations between SVR12 and different baseline factors in 
the two studies (Table S3). In HCVerso1, there was a signifi-
cant association between SVR12 and duration of treatment 
(P=0.0226, odds ratio [OR] 24-week noncirrhotic vs 16-week 
noncirrhotic 2.079, 95% CI 1.230–3.513; OR 24-week cir-
rhotic vs 16-week noncirrhotic 1.195, 95% CI 0.552–2.586), 
IL28B rs12979860 (CC vs nonCC genotype, P=0.0051, OR 
2.538, 95% CI 1.322–4.873), sex (male vs female, P=0.0089, 
OR 0.517, 95% CI 0.315–0.847), and region (North America 
vs Europe, P=0.0029, OR 0.435, 95% CI 0.252–0.753). In 
HCVerso2, factors found to be significantly associated with 
SVR12 were IL28B rs12979860 (CC vs nonCC genotype 
Table 1 Baseline demographics and clinical characteristics
Characteristic HCVerso1 FDV + DBV + RBV HCVerso2 FDV + DBV + RBV
16 weeks 
(n=208)
24 weeks 
(n=211)
24 weeks (C) 
(n=51)
16 weeks 
(n=213)
24 weeks 
(n=211)
24 weeks (C) 
(n=72)
Male, n (%) 86 (41) 97 (46) 33 (65) 93 (44) 103 (49) 45 (63)
Race, n (%)
 White 185 (89) 192 (91) 47 (92) 194 (91) 197 (93) 70 (97)
 Black or AA 17 (8) 12 (6) 3 (6) 13 (6) 5 (2) 1 (1)
 Asian 5 (2) 7 (3) 1 (2) 5 (2) 9 (4) 1 (1)
 Other 1 (1) 0 0 1 (1) 0 0
Region, n (%)
 North America 43 (21) 42 (20) 9 (18) 58 (27) 43 (20) 16 (22)
 Europe 165 (79) 169 (80) 42 (82) 141 (66) 146 (69) 47 (65)
 Australia/New Zealand NA NA NA 14 (7) 22 (10) 9 (13)
Mean age, years (SD) 50 (13) 51 (13) 58 (9) 51 (12) 50 (13) 58 (9)
Mean BMI, kg/m2 (SD) 26 (4) 25 (4) 27 (4) 27 (5) 26 (5) 27 (4)
IL28B rs12979860, n (%)
 CC 50 (24) 50 (24) 14 (28) 50 (24) 54 (26) 18 (25)
 CT 117 (56) 113 (54) 28 (55) 125 (59) 107 (51) 41 (57)
 TT 34 (16) 37 (18) 7 (14) 32 (15) 40 (19) 9 (13)
 Missing 7 (3) 11 (5) 2 (4) 6 (3) 10 (5) 4 (6)
Mean HCV RNA, log10 IU/mL (SD) 6.4 (0.6) 6.3 (0.8) 6.5 (0.5) 6.4 (0.6) 6.4 (0.7) 6.4 (0.8)
HCV RNA category, n (%)
 <800,000 IU/mL 34 (16) 47 (22) 7 (14) 38 (18) 39 (19) 20 (28)
  ≥800,000 IU/mL 174 (84) 164 (78) 44 (86) 175 (82) 172 (82) 52 (72)
Fibrosis stage, n (%)a
 F0–F2 162 (78) 169 (80) 0 183 (86) 165 (78) 0
 F3 38 (18) 38 (18) 0 23 (11) 42 (20) 0
 F4 0 0 51 (100) 1 (1)b 0 72 (100)
 Missingc 8 (4) 4 (2) 0 6 (3) 4 (2) 0
PegIFN eligible,d n (%) NA NA NA 187 (88) 184 (87) 60 (83)
Notes: aFibroScan results were used to determine stage of fibrosis for patients without a liver biopsy (<9.5 kPa = F0–F2; ≥9.5–<13 kPa = F3; ≥13 kPa = F4). bAssignment to 
Arm 3, cirrhosis, was based on investigator’s assessment for the presence of cirrhosis. This patient had no clinical evidence of cirrhosis per investigator; however, screening 
FibroScan was ≥13kPa. cIn patients with missing fibrosis data, cirrhosis was excluded, but further details on fibrosis staging were not available. dPegIFN eligibility was based 
on the investigators’ clinical judgment and determined at the randomization visit.
Abbreviations: AA, African-American; BMI, body mass index; C, compensated cirrhosis; DBV, deleobuvir; FDV, faldaprevir; HCV, hepatitis C virus; NA, not applicable; 
PegIFN, pegylated interferon-α; RBV, ribavirin; SD, standard deviation.
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P=0.0108, OR 2.239, 95% CI 1.205–4.163), baseline HCV 
RNA (≥800,000 vs <800,000 IU/mL, P=0.0195, OR 0.436, 
95% CI 0.217–0.875), and sex (male vs female, P=0.0071, 
OR 0.514, 95% CI 0.316–0.835).
Resistance
Baseline genotypic analysis of HCV GT-1b NS3/4A and 
NS5B population-based sequences was available for samples 
from 460 and 462 patients, respectively, in HCVerso1, and 
for 490 patients each in HCVerso2. Resistance-associated 
variants (RAVs) were detected in baseline samples from a 
minority of these patients. In the NS3 domain, no RAVs were 
detected at R155 or A156 in either study; D168E was detected 
in seven (1.5%) samples in HCVerso1 and in three (0.6%) 
samples in HCVerso2. In the NS5B domain, the most fre-
quently detected baseline RAVs in HCVerso1 and HCVerso2 
were A421V (43 [9%] and 40 [8%], respectively), V499A (69 
[15%] and 77 [16%], respectively), and V499T/I/L (28 [6%] 
and 33 [7%], respectively), whereas no baseline RAVs were 
detected at NS5B P495. SVR12 rates for patients with NS5B 
A421V or V499A polymorphisms are summarized in Table 4.
HCV genotypic analysis of samples from patients 
who received active treatment and failed to achieve 
SVR12 was available for 86 patients in HCVerso1 and 
93 patients in HCVerso2. Overall, the most frequent 
(>10%) treatment-emergent RAVs detected were: in 
the NS3 domain, D168V (27 [31%] and 32 [34%] in 
HCVerso1 and HCVerso2, respectively) and D168T (11 
[13%] in HCVerso1); and in the NS5B domain, P495L 
(34 [40%] and 37 [39%] in HCVerso1 and HCVerso2, 
respectively) and P495Q (9 [10.5%] in HCVerso1). All 
on-treatment failures had RAVs in NS3 and/or NS5B and 
Figure 2 Adjusted SVR12 versus historical control for HCVerso1 (A) and HCVerso2 (C), and SVR12 by treatment group for HCVerso1 (B) and HCVerso2 (D)
Notes: aAdjusted for inclusion of patients with cirrhosis (11% in historical trials of approved DAAs and PegIFN). bCombination of the rates for 16 weeks in patients without 
cirrhosis and 24 weeks in patients with cirrhosis. Error bars indicate 95% CI values.
Abbreviations: C, compensated cirrhosis; CI, confidence interval; SVR12, sustained virologic response at 12-week posttreatment; wks, weeks.
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most frequently in both (92.5% [37/40] in HCVerso1 and 
97.5% [39/40] in HCVerso2) (Figure S2). Among patients 
with relapse, RAVs at both loci were detected in most 
samples (68% [17/25] and 54% [14/26] in HCVerso1 and 
HCVerso2, respectively), with RAVs at a single locus 
(either NS3 or NS5B) detected in 24% (6/25) in HCVerso1, 
27% (7/26) in HCVerso2, and no RAVs detected in the 
remaining relapse samples. Among patients who discon-
tinued active treatment prematurely, most had no RAVs 
detected among their post baseline samples (81% [17/21] 
in HCVerso1 and 56% [15/27] in HCVerso2).
Safety and tolerability
The incidence of AEs, serious AEs, and AEs leading to dis-
continuation of study treatment was similar across treatment 
groups for both studies (Table 5). Most AEs were considered 
related to treatment. The most common AEs were nausea, 
vomiting, and diarrhea. AEs were mostly mild or moderate 
with onset within the first 8 weeks of treatment. AEs led to 
discontinuation of all medication in 6%–8% of patients. The 
most frequent AEs leading to discontinuation were nausea 
(7 [1.5%] patients in HCVerso1 and 3 [0.6%] in HCVerso2) 
and vomiting (7 [1.5%] patients in HCVerso1 and 6 [1.2%] 
in HCVerso2). Rash and photosensitivity were mostly mild: 
for photosensitivity, 89/100 (89%) cases in HCVerso1 
and 84/100 (84%) cases in HCVerso2 were mild; for rash, 
109/111 (98%) cases in HCVerso1 and 149/157 (95%) cases 
in HCVerso2 were mild. The most frequently reported seri-
ous AE was anemia (three patients in HCVerso1 and four in 
HCVerso2). There was one death, in HCVerso1, which was 
due to an accidental fall and not considered related to the study 
treatment.
Table 2 Virologic response rates (intention-to-treat population)
Virologic response, n (%) HCVerso1 FDV + DBV + RBV HCVerso2 FDV + DBV + RBV
16 weeks 
(n=208)
24 weeks 
(n=211)
24 weeks (C) 
(n=51)
16 weeks 
(n=213)
24 weeks 
(n=211)
24 weeks (C) 
(n=72)
Week 4 virologic response 
≥25 IU/mL
<25 IU/mL, detected
<25 IU/mL, undetected
2 (1.0)
47 (22.6)
148 (71.2)
2 (0.9)
56 (26.5)
151 (71.6)
4 (7.8)
11 (21.6)
32 (62.7)
2 (0.9)
36 (16.9)
162 (76.1)
4 (1.9)
47 (22.3)
150 (71.1)
4 (5.6)
19 (26.4)
49 (68.1)
ETR, undetected 181 (87.0) 188 (89.1) 40 (78.4) 183 (85.9) 183 (86.7) 61 (84.7)
SVR4 (<25 IU/mL) 163 (78.4) 178 (84.4) 39 (76.5) 171 (80.3) 177 (83.9) 56 (77.8)
SVR12 (<25 IU/mL) 149 (71.6) 174 (82.5) 37 (72.5) 161 (75.6) 173 (82.0) 53 (73.6)
SVR12 by Week 4 responsea
≥25 IU/mL
<25 IU/mL, detected
<25 IU/mL, undetected
Missingb
1/2 (50.0)
30/47 (63.8)
118/148 (79.7)
0/11 (0)
0/2 (0)
43/56 (76.8)
131/151 (86.8)
0/2 (0)
1/4 (25.0)
9/11 (81.8)
27/32 (84.4)
0/4 (0)
0/2 (0)
26/36 (72.2)
135/162 (83.3)
0/13 (0)
0/4 (0)
43/47 (91.5)
130/150 (86.7)
0/10 (0)
0/4 (0)
15/19 (79.0)
38/49 (77.6)
0/0
Notes: an/N (%), where N = number with indicated Week 4 virologic response; n = number with SVR12. bNone had virologic breakthrough.
Abbreviations: C, compensated cirrhosis; DBV, deleobuvir; ETR, end of treatment response (HCV RNA <25 IU/mL, target not detected at the end of planned treatment); 
FDV, faldaprevir; HCV, hepatitis C virus; RBV, ribavirin; SVR4/12, virologic response at 4 or 12 weeks after the end of treatment.
Table 3 Reasons for not achieving SVR12
n (%) HCVerso1 FDV + DBV + RBV HCVerso2 FDV + DBV + RBV
16 weeks 
(n=208)
24 weeks 
(n=211)
24 weeks (C) 
(n=51)
16 weeks 
(n=213)
24 weeks 
(n=211)
24 weeks (C) 
(n=72)
Not achieving SVR12 59 (28) 37 (18) 14 (28) 52 (24) 38 (18) 19 (26)
Virologic failure on treatment
 Breakthrough on or before 16 weeks
 Breakthrough after 16 weeks
 Lack of ETRa
15 (7)
14
0
1
20 (9)
18
2
0
7 (14)
6
0
1
16 (8)
16
0
0
17 (8)
13
3
1
9 (13)
7
0
2
Relapseb 23 (11) 3 (1) 2 (4) 18 (9) 3 (1) 6 (8)
Premature discontinuation (for reasons 
other than lack of efficacy)
18 (9) 11 (5) 5 (10) 18 (9) 17 (8) 4 (6)
Lost to follow-up (completed treatment) 3 (1) 3 (1) 0 0 1 (<1) 0
Notes: aPatients without virologic breakthrough who had HCV RNA detectable at the EOT. bRelapse rates, based on the number of patients who completed planned 
treatment and had HCV RNA undetectable at EOT, were: HCVerso1 13% (23/175), 2% (3/167), and 5% (2/37) in the 16-, 24-, and 24-week cirrhotic groups, respectively; 
HCVerso2 10% (18/174), 2% (3/169), and 11% (6/56) in the 16-, 24-, and 24-week cirrhotic groups, respectively.
Abbreviations: C, compensated cirrhosis; DBV, deleobuvir; EOT, end of treatment; ETR, end of treatment response (HCV RNA <25 IU/mL, target not detected at the end 
of planned treatment); FDV, faldaprevir; HCV, hepatitis C virus; RBV, ribavirin; SVR12, sustained virologic response at 12-week posttreatment.
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There was one case of Grade 4 neutropenia that occurred 
after 12 weeks of treatment in HCVerso1 and was considered 
by the investigator to be probably related to the study drugs 
(Table 5). Grade 3 or 4 bilirubin elevations were observed in 
around half of all patients (Table 5). Bilirubin elevations were 
characterized mainly by unconjugated bilirubin, and biliru-
bin levels returned to baseline shortly after the end of active 
treatment (Figure S3). In HCVerso1, no patient experienced 
both ALT ≥3 × upper limit of normal (ULN) or baseline and 
total bilirubin >2 × ULN with a direct:indirect bilirubin ratio 
>1. In HCVerso2, one patient with baseline cirrhosis expe-
rienced a cholestatic injury pattern after 12 weeks of trial 
treatment with ALT 5 × ULN, total bilirubin >2 × ULN with 
a direct:indirect bilirubin ratio >1, and alkaline phosphatase 
Figure 3 SVR12 for 24-week versus 16-week regimen by subgroups in HCVerso1 (A) and HCVerso2 (B)
Notes: aNo patient in the 16-week or 24-week non-cirrhotic arms had fibrosis stage F4.
Abbreviations: AA, African-American; CI, confidence interval; GGT, gamma-glutamyl transferase; PegIFN, peginterferon-α; VL, viral load; wks, weeks.
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Table 4 SVR12 rates among patients with HCV NS5B resistance-
associated variants at baseline
HCV baseline 
polymorphisms
SVR12 n/Na (%)
HCVerso1 HCVerso2
A421V Present
Absent
25/31 (81)
330/390 (85)
P=0.606b
27/32 (84)
356/418 (85)
P=0.801b
V499A Present
Absent
37/50 (74)
318/371 (86)
P=0.039b
51/64 (80)
301/351 (86)
P=0.188b
V499T Present
Absent
16/20 (80)
339/401 (85)
P=0.534b
24/27 (89)
359/423 (85)
P=0.782b
Notes: aN = patients evaluable for SVR12, excluding those who discontinued 
treatment prematurely for reasons other than virologic failure. bTwo-sided Fisher’s 
exact test comparing percentages of patients who achieved a virologic response 
with and without a specific baseline amino acid variant (“present” does not include 
the variants detected as a mixture with other amino acids).
Abbreviations: HCV, hepatitis C virus; SVR12, sustained virologic response at 
12-week posttreatment.
elevations  following administration of amoxicillin/clavulanate 
potassium (Augmentin®); the internal hepatic advisory com-
mittee determined that the case was not study drug-induced 
liver injury, but was more likely related to amoxicillin/cla-
vulanate potassium use. All laboratory abnormalities in this 
patient resolved with discontinuation of medications.
Discussion
In these two large Phase III clinical studies, 24 weeks of the 
IFN-free combination of faldaprevir, deleobuvir, and ribavirin 
in treatment-naïve, HCV GT-1b-infected patients resulted in 
higher adjusted rates of SVR12 than historical control rates 
based on a first-generation protease inhibitor plus PegIFN 
and ribavirin. Results for the 16-week treatment arms differed 
between the two studies. In HCVerso2, SVR12 following 
16 weeks of treatment remained superior to the historical 
control and was not significantly lower than the SVR12 after 
24 weeks of treatment. However, in HCVerso1, 16 weeks of 
treatment resulted in an SVR12 rate that was significantly 
lower than that achieved with 24 weeks of treatment (72% 
vs 82%, respectively, P=0.0040) and was not superior to the 
historical control. Notably, the rate of relapse in the 16-week 
treatment arms was higher than in the 24-week treatment 
arms in both studies. Assessment of SVR12 rates according 
to virologic response at Week 4 showed higher response rates 
among patients who had HCV RNA undetected at Week 4 
than among those with HCV RNA <25 IU/mL detected at 
Week 4 in the 16-week treatment arm. The impact of Week 
4 responses on SVR12 was less pronounced in the 24-week 
treatment arms, including among those with cirrhosis. The 
studies included a total of 123 patients with compensated 
cirrhosis; these patients achieved SVR12 rates of 73% in 
HCVerso1 and 74% in HCVerso2 after 24 weeks of treatment. 
Data from studies using other all-oral DAA regimen suggest 
that patients with cirrhosis may require longer treatment dura-
tions to achieve SVR than patients without cirrhosis.2 How-
ever, failure to achieve SVR12 in patients with cirrhosis in the 
HCVerso studies was mostly due to virologic breakthrough 
or  premature discontinuation due to AEs, with a low rate of 
posttreatment relapse, suggesting that an extended treatment 
duration would not improve the response rate.
RAVs present prior to the initiation of treatment have the 
potential to compromise the response to antiviral treatment. 
Consistent with previous observations,26 NS3 R155 and 
D168 RAVs associated with resistance to faldaprevir were 
infrequently detected at baseline in the HCVerso studies. 
The NS5B RAVs A421V and V499A were more common 
at baseline (83/922 [9%] and 146/922 [16%], respectively). 
The baseline RAVs NS5B A421V and V499A have been 
shown to confer low-level resistance to deleobuvir in vitro 
(<sixfold decrease in potency).17 Baseline A421V had no 
impact on SVR12. A reduction in SVR12 may be associated 
with baseline V499A among a small subset of patients, as 
was noted in HCVerso1 (74% [37/50] SVR12 with V499A 
vs 86% [318/371] SVR12 without V499A, P=0.039). 
Virologic failure resulted in the selection of multiple RAVs 
in most cases: samples from the majority of patients with 
virologic failure had RAVs in both the NS3 and NS5B 
domains,  predominantly encoding NS3 D168V and NS5B 
P495L. Faldaprevir Phase 1b/2 studies have indicated that 
NS3 D168 RAVs have shorter posttreatment persistence 
and are less fit compared with NS3 R155 RAVs,27,28 such 
as the GT-1a R155K RAV, which has been reported to have 
a median time to loss of 9.8 months.29 From earlier studies 
of deleobuvir,17,30 P495 RAVs selected during breakthrough 
were rapidly outgrown by wild-type virus in the absence of 
drug selective pressure; for example, P495 RAVs persisted 
up to 8 weeks after the EOT and were no longer detected by 
the end of follow-up (68 weeks after EOT).30
Overall, the tolerability profile for the faldaprevir, dele-
obuvir, ribavirin combination was less favorable than that 
recently reported for other all-DAA regimens.31 Reported 
AEs in both the studies were predominantly mild or moderate 
in severity (with onset within the first 8 weeks of treatment), 
were similar in the 16- and 24-week treatment arms, and 
were consistent with the safety profiles previously reported 
for deleobuvir and faldaprevir.19–21 Photosensitivity and rash 
both occurred in around 20% of patients and were mostly 
mild. The most frequently reported AEs were gastrointestinal. 
Nausea and vomiting were the most common AEs leading 
to premature discontinuation of all treatments. Bilirubin 
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Table 5 Overview of AEs
Patients with AEs, n (%) HCVerso1 FDV + DBV + RBV HCVerso2 FDV + DBV + RBV
16 weeks 
(n=208)
24 weeks 
(n=211)
24 weeks (C) 
(n=51)
16 weeks 
(n=213)
24 weeks 
(n=211)
24 weeks (C) 
(n=72)
Any AE 200 (96) 202 (96) 51 (100) 208 (98) 206 (98) 67 (93)
AE considered related to treatment, n (%) 178 (86) 185 (88) 49 (96) 192 (90) 196 (93) 61 (85)
AE leading to discontinuation of all medications 16 (8) 16 (8) 4 (8) 14 (7) 14 (7) 4 (6)
AE leading to discontinuation of RBV 1 (0.5) 1 (0.5) 1 (2) 3 (1) 4 (2) 2 (3)
RBV dose reduction/interruption 28 (13)/8 (4) 47 (22)/8 (4) 19 (37)/3 (6) 34 (16)/13 (6) 38 (18)/6 (3) 15 (21)/5 (7)
Grade ≥3 AEsa 32 (15) 42 (20) 10 (20) 24 (11) 27 (13) 12 (17)
Grade 4 AEsa 5 (2) 4 (2) 2 (4) 5 (2) 4 (2) 3 (4)
Serious AEsb 7 (3) 11 (5) 4 (8) 12 (6) 7 (3) 8 (11)
Deaths 1 (0.5) 0 0 0 0 0
Most frequent AEs (>20% in any group)
 Nausea
 Vomiting
 Diarrhea
 Fatigue
 Pruritus
 Rashc
 Photosensitivityc,d
 Asthenia
 Anemia
96 (46)
64 (31)
50 (24)
53 (26)
37 (18)
47 (23)
39 (19)
40 (19)
41 (20)
112 (53)
62 (29)
66 (31)
50 (24)
53 (25)
49 (23)
47 (22)
58 (28)
55 (26)
27 (53)
18 (35)
17 (33)
13 (26)
20 (39)
15 (29)
14 (27)
7 (14)
19 (37)
121 (57)
64 (30)
56 (26)
74 (35)
47 (22)
62 (29)
41 (19)
35 (16)
24 (11)
129 (61)
69 (33)
59 (28)
74 (35)
47 (22)
68 (32)
49 (23)
44 (21)
27 (13)
41 (57)
25 (35)
23 (32)
26 (36)
23 (32)
27 (38)
10 (14)
18 (25)
14 (19)
Grade ≥3 laboratory abnormalitiesa,e
 Hemoglobin (<9 g/dL)
 White blood cells (<1,500/mm3)
 Platelets (<50,000/mm3)
 Lymphocytes (<500/mm3)
 Neutrophils (<750/mm3)
 AST
 ALT
 Creatinine
 Total bilirubin (>2.5 × ULN), G3/G4
29 (14)
0
0
1 (<1)f
2 (1)
0
0
0
83 (40)/22 (11)
0 (14)
2 (1)
0
1 (<1)
3 (1)f,g
1 (<1)
1 (<1)
1 (<1)f
87 (41)/25 (12)
8 (16)
1 (2)
0
2 (4)
1 (2)
0
0
0
22 (43)/5 (10)
29 (14)
0
0
0
1 (<1)
4 (2)
10 (5)f
2 (1)f
73 (34)/19 (9)
30 (14)
0
0
1 (<1)
1 (<1)
1 (<1)
1 (<1)
0
74 (36)/23 (11)
22 (31)
0
1 (1)
0
0
0
0
0
43 (60)/4 (6)
Notes: aSeverity based on Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events: Grade 3 = severe, Grade 4 = potentially life-threatening. 
bHCVerso 1 serious AEs included the following: in the 16-week group, anemia, decreased appetite, dizziness, and fatigue (1), agranulocytosis (1), non-Hodgkin’s lymphoma 
(1), pancreatic carcinoma (1), loss of consciousness (1), fall and multiple injuries (1), and pericarditis (1); in the 24-week group, agranulocytosis and febrile neutropenia (1), 
duodenal ulcer, gastroesophageal reflux disease, bacterial gastritis, and gingivitis (1), acute renal failure (1), anemia (1), depression (1), psychotic disorder (1), syncope, fall, and 
hematoma (1), Escherichia urinary tract infection, anemia, and pyrexia (1), postgastric surgery syndrome (1), thrombosis (1), and arthritis (1); in the 24-week cirrhotic group, 
diarrhea (1), gastrointestinal hemorrhage, hyperbilirubinemia, and prerenal failure (1), cholelithiasis (1), and urethral stenosis (1). HCVerso2 serious AEs included the following: 
in the 16-week group, anemia (1), anemia, diarrhea, fatigue, and acute prerenal failure (1), vomiting and diarrhea (1), vomiting and hematemesis (1), pancreatitis (1), tonsillitis 
(1), hepatocellular carcinoma (1), prostate cancer (1), depression and suicide attempt (1), bipolar I disorder (1), depression and insomnia (1), and acute renal failure (1); in the 
24-week group, anemia and thrombocytosis (1), pneumonia (1), basal cell carcinoma (1), depression (1), drug eruption (1), drug hypersensitivity (1), and fall, jaw fracture, loss 
of consciousness, and malaise (1); in the 24-week cirrhotic group, anemia and pneumonia (1), cellulitis, febrile neutropenia, hyperbilirubinemia, and hepatocellular carcinoma 
(1), gastric ulcer (1), gastrointestinal hemorrhage and portal hypertensive gastropathy (1), pericarditis (1), amnesia (1), photosensitivity reaction (1), and hypertensive crisis (1). 
cComposite term Boehringer Ingelheim customized MedDRA query. dPatients were instructed to avoid direct sun exposure as much as possible and to apply UVA and UVB 
sun-blocking cream to any uncovered skin daily during treatment. eAll Grade 3 unless otherwise indicated. fOne Grade 4. gOccurred at or after Week 12.
Abbreviations: AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; C, compensated cirrhosis; DBV, deleobuvir; FDV, faldaprevir; RBV, 
ribavirin; ULN, upper limit of normal; UVA, ultraviolet A; UVB, ultraviolet B.
elevations were common, but were mainly the result of an 
increase in unconjugated bilirubin, were not associated with 
ALT elevations, and returned to baseline levels immediately 
after the EOT. There were no cases of drug-induced liver 
injury. One patient experienced Grade 4 neutropenia. Across 
clinical studies with deleobuvir, Grade 4 neutropenia has been 
reported for four out of approximately 1,400 patients. All 
events occurred after at least 12 weeks of treatment, which 
is not typical of drug-induced neutropenia. Three patients 
fully recovered after treatment discontinuation. The remain-
ing patient recovered after a 5-day treatment discontinuation, 
 following which treatment was reinitiated with no recurrence 
of neutropenia.
Limitations
The HCVerso studies have some limitations. The use of 
historical controls is subject to potential bias, particularly 
when, as in these studies, adjustments are needed to account 
for differences between control and study patient populations. 
In addition, the field of HCV treatment has moved rapidly 
since the initiation of these studies, such that the historical 
controls used are already not representative of the current 
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standard of care. Historical controls were based on treatment 
regimen comprising a first-generation protease inhibitor plus 
PegIFN/ribavirin. New all-oral DAA combinations are now 
available for patients with HCV GT-1b infection and have 
demonstrated the potential for SVR12 rates of >90% with 
treatment durations as short as 12 weeks.11,13 Therefore, based 
on the results of the HCVerso studies, Boehringer Ingelheim 
has decided not to move forward in this therapeutic area.
Conclusions
In conclusion, in treatment-naïve, noncirrhotic patients with 
HCV GT-1b infection, faldaprevir + deleobuvir + ribavirin for 
16 or 24 weeks resulted in SVR12 rates of between 71.6% and 
82.5%. Although the adjusted SVR12 rates for 24 weeks of 
treatment were significantly higher than historical controls in 
both studies, they were lower than expected. No justification 
could be made for the shorter and more desirable 16-week 
treatment duration because it resulted in a higher rate of 
relapse than the 24-week arms in both studies.
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